Type of information: Licensing agreement
Compound: emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody)
Company: Chugai Pharmaceutical (Japan) JW Pharmaceutical (Republic of Korea)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: licensing
Action mechanism: bispecific antibody. Emicizumab is a bispecific antibody that mimics coagulation factor VIII. The drug is designed to bind factors lXa and factors X, and promotes the interaction between factors lXa and factors X. In doing so, emicizumab provides the cofactor function of factor Vlll in people with hemophilia A, who either lack or have impaired coagulation function of factor Vlll). It is currently investigated as a therapy for people with hemophilia A. Emicizumab was designated as a Breakthrough Therapy by the FDA in September 2015. This antibody is under co-development by Chugai, Roche and Genentech.
Disease: hemophilia A
Financial terms: Based on the agreement, Chugai will receive upfront, milestone payment and sales-tied royalties.